Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
02:26pm, Tuesday, 23'rd Jan 2024
Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
3 Stocks to Buy Now Before They Become Tomorrow's Trillion-Dollar Companies
01:30pm, Wednesday, 27'th Dec 2023
Heading into 2024, the future of the U.S. economy remains uncertain, with conflicting predictions about the possibility of a recession. While some experts anticipate a soft landing, others predict a m
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
11:18am, Friday, 22'nd Dec 2023
FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
08:43pm, Thursday, 21'st Dec 2023
Ionis Pharmaceuticals IONS, +1.61% and AstraZeneca's AZN, +0.79% Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
07:05am, Wednesday, 20'th Dec 2023
CARLSBAD, Calif. , Dec. 20, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
12:02pm, Tuesday, 19'th Dec 2023
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
Ionis Pharmaceuticals: Pioneering Precision Medicine
06:01pm, Monday, 04'th Dec 2023
Ionis Pharmaceuticals is focused on developing and strengthening its position in the oligonucleotide therapeutics sector. Oligonucleotide therapeutics offer a novel method for treating diseases by alt
Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise
11:18am, Monday, 13'th Nov 2023
Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.
Ionis to present at upcoming investor conferences
07:05am, Friday, 03'rd Nov 2023
CARLSBAD, Calif. , Nov. 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Gug
Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript
05:20pm, Thursday, 02'nd Nov 2023
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2023 Earnings Conference Call November 2, 2023 11:30 AM ET Company Participants Wade Walke - Senior Vice President, Investor Relations Brett Monia - Chief
Ionis to hold third quarter 2023 financial results webcast
07:05am, Thursday, 19'th Oct 2023
Webcast scheduled for Thursday, November 2 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
11:17am, Thursday, 28'th Sep 2023
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?
09:01am, Wednesday, 27'th Sep 2023
Ionis Pharmaceuticals (IONS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price
Ionis Pharma's genetic disorder drug meets main goal in late-stage study
07:13am, Tuesday, 26'th Sep 2023
Ionis Pharmaceuticals said on Tuesday its experimental drug met main goal in a late-stage trial testing it as a treatment for a rare genetic disorder known as familial chylomicronemia syndrome.
